Resmetirom: acts on the MASH and fibrosis regression by intrahepatic path Resmetirom is an orally administered, liver-targeted thyroid hormone receptor- (THR) selective agonist
IV Nutrient Therapy and Wellness Boosts: Targeted IV infusions and wellness protocols to address dehydration, nutrient gaps, and acute recovery needs, always chosen after reviewing medical history and goals
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of drugs commonly used to manage type 2 diabetes and, more recently, obesity
Data were evaluated for statistical significance by a paired t test
Unknown Long-Term Effects: Additionally, long-term effects remain largely unexplored, raising questions about sustained efficacy and safety
The relationship between testosterone and GLP-1 is important because excess body fat can lower natural testosterone levels